Recently presented findings in AD have clinical implications now and in the long-term.
By Ronald Devere, MD
Specialists share insights on diagnostic tools, prospects for neuroprotective therapies, and the risk of MS.
By Paul Winnington, Editorial Director
Aspirin resistance is a controversial issue with important clinical implications for neurologists and patients.
By James C. Grotta, MD
As the details of healthcare reform take shape, an ASP may provide a cost-efficient way for clinicians to go digital.
By Mark Kaufmann, MD
A mixture of multiple pathologies may contribute to dementia in most elderly beyond the age of 80.
By Majid Fotuhi, MD, PhD
A simple test can easily determine the presence of small fiber neuropathy. Here’s what you need to know.
By David S. Saperstein, MD and Todd D. Levine, MD
Pseudotumor cerebri occurs in about one in 1,000 people, and a “cause” is often difficult to identify.
By Lenworth N. Johnson, MD
By Paul Winnington Editorial Director
An effort by Hawaii lawmakers to score lower drug prices for seniors by shipping cheap prescriptions from Canada received a deathblow from a combination of politics and unprofitability, according to the AP. Citing fears of leg... more >
The Centers for Disease Control and Prevention along with the AAN are asking neurologists to watch for a rare swine flu vaccine side effect, Guillain-Barre syndrome (GBS). During a 1976 outbreak, swine flu vaccine was linked t... more >
When the issue of freedom of speech enters the debate in the US, usually publishers or protestors come to mind, not Big Pharma. But a new lawsuit announced October 1 and brought by Allergan is claiming that the government has ... more >
The importance of early treatment initiation in MS seems to be reinforced by the Phase III PreCISe trial. According to a publication this month in The Lancet, glatiramer acetate (Copaxone, Teva) reduced the risk of developing c... more >
A simple test can easily determine the presence of small fiber neuropathy. Here’s what you need to know.
by David S. Saperstein, MD and Todd D. Levine, MD
Specialists share insights on diagnostic tools, prospects for neuroprotective therapies, and the risk of MS.
by Paul Winnington, Editorial Director
Pseudotumor cerebri occurs in about one in 1,000 people, and a “cause” is often difficult to identify.
by Lenworth N. Johnson, MD
Recently presented findings in AD have clinical implications now and in the long-term.
by Ronald Devere, MD